UBS Reiterates Neutral on Novo Nordisk A/S (NVO) Despite Wegovy Dose Progress

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. 

On December  15, 2025, UBS reaffirmed its Neutral (Hold) rating on NVO with an unchanged price target of DKK 295, reflecting a cautious view on the stock amid competitive pressures and mixed industry dynamics. UBS’s rating and target were reiterated in recent analyst research, with the Neutral outlook suggesting neither strong upside nor a compelling near‑term buy signal.

A key recent development supporting Novo Nordisk A/S (NYSE:NVO)’s growth strategy occurred on December  12, 2025, when the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion recommending EU approval of a higher 7.2 mg dose of Wegovy (semaglutide). This higher dose demonstrated significantly greater average weight loss in clinical trials compared to the currently approved 2.4 mg dose and, if formally approved by the European Commission, could become available in early 2026.

The higher Wegovy dosage is also under regulatory review in the U.S., U.K., and other regions, with NVO having submitted the filing in the U.S. and receiving an expedited review designation.

Novo Nordisk A/S (NYSE:NVO) is a Danish multinational pharmaceutical company. It is a world leader in diabetes and obesity care, producing approximately half of the world’s insulin.

While we acknowledge the risk and potential of NVO as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than NVO and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Blue Chip Stocks to Buy Under $50 and11 Best Low Priced Dividend Stocks to Buy According to Analysts.

Disclosure: None.